Articles from BioAdaptives, Inc.

Zero-login digital companion offers immediate breathing resets and vetted trauma support today, while Xycota prepares preclinical BDNF/TrkB psilocybin research for practical outpatient care.Free, Off-Record PTSD Support Available Today: Live at https://xycota.com/ptsd, the free hub requires no account or cloud data storage and offers guided 60-second physiological sigh, box breathing, and 5-4-3-2-1 sensory grounding tools, a private browser-only log, and a confidential support matcher for veterans, first responders, and families.Sub-Perceptual, At-Home Psilocybin Research (XYCO-02): Alongside free community tools, Xycota is preparing a Canadian clinical trial application with KGK Science to test whether low-dose oral psilocybin can engage the brain's BDNF/TrkB repair pathway at home without a six-to-eight-hour clinic trip.Two-Company Structure and Shareholder Safeguards: BioAdaptives, Inc.'s (OTCID:BDPT) definitive agreement to acquire Xycota keeps biotech and nutraceutical operations separate, includes conditional funding for a proposed nutraceutical spin-off, and enforces a 12-month founder lock-up and daily note resale limits.

Xycota's lead program aims to deliver clinical benefit from low-dose psilocybin without hallucinogenic effects, with mild PTSD as its initial target.

UFC Hall of Famer and MyndSystem™ brand ambassador shares how the daytime formula fits into his preparation for live broadcasts, commentary, and podcasting.

Initial XcellaraHeart™ orders ship next week, marking the commercial launch of the Xcellara™ cellular wellness platform; Company prepares XcellaraResilience™ for October launch and highlights the retirement of major convertible debt and 43.25M insider shares.

Former UFC middleweight champion and current broadcaster will help promote MyndSystem™ as part of a disciplined day-and-night performance routine

Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure.

The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks.

Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform

Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches.

LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront operations and direct-to-consumer (DTC) marketing footprint for its flagship cognitive performance line, MyndSystem™.